OTC Markets OTCQX - Delayed Quote
USD
Bayer Aktiengesellschaft (BAYRY)
14.21
-0.16
(-1.11%)
As of 12:11:01 PM EDT. Market Open.
Loading chart for BAYRY
- Previous Close
14.37 - Open
14.17 - Bid 14.17 x 150000
- Ask 14.19 x 597900
- Day's Range
14.10 - 14.21 - 52 Week Range
7.48 - 15.23 - Volume
10,314 - Avg. Volume
1,098,617 - Market Cap (intraday)
55.841B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.51 - Earnings Date (est.) Nov 3, 2026
- Forward Dividend & Yield 0.03 (0.22%)
- Ex-Dividend Date Apr 28, 2026
- 1y Target Est
15.90
Recent News
View More
Performance Overview
Trailing total returns as of 8/20/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
BAYRY
31.85%
DAX P (^GDAXI)
6.09%
1-Year Return
BAYRY
75.52%
DAX P (^GDAXI)
7.03%
3-Year Return
BAYRY
4.65%
DAX P (^GDAXI)
66.83%
5-Year Return
BAYRY
11.08%
DAX P (^GDAXI)
64.37%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/18/2026
-
Market Cap
55.74B
-
Enterprise Value
88.84B
-
Trailing P/E
--
-
Forward P/E
10.94
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
1.06
-
Price/Book (mrq)
1.62
-
Enterprise Value/Revenue
1.69
-
Enterprise Value/EBITDA
15.81
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-3.83%
-
Return on Assets (ttm)
3.18%
-
Return on Equity (ttm)
-5.69%
-
Revenue (ttm)
45.38B
-
Net Income Avi to Common (ttm)
-1.74B
-
Diluted EPS (ttm)
-0.51
Balance Sheet and Cash Flow
-
Total Cash (mrq)
5.08B
-
Total Debt/Equity (mrq)
129.36%
-
Levered Free Cash Flow (ttm)
6.56B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
18.10
+2.90%
Mkt Cap
32.936B
Industry
Drug Manufacturers—General
Mkt Cap
undefined
-
Industry
-
Research Reports
View More-
Bayer Earnings: Crop Science Shines; Litigation Overhang Significantly Lighter
Bayer is a German healthcare and agriculture conglomerate. Healthcare accounts for close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total sales). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, a segment that was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target -
Bayer AG: Supreme Court Decision on Durnell Case Improves Outlook for Crop Science
Bayer is a German healthcare and agriculture conglomerate. Healthcare accounts for close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total sales). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, a segment that was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target -
Bayer AG: Supreme Court Decision on Durnell Case Improves Outlook for Crop Science
Bayer is a German healthcare and agriculture conglomerate. Healthcare accounts for close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total sales). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, a segment that was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target -
Bayer Earnings: On Track to Deliver Full-Year Guidance
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target
